Anti-PD1/PD-1 inhibitors demonstrate a lobular inflammation with CD4+/CD8+ T cells, while anti-CTL4 inhibitors may have central vein endotheliosis and non-necrotizing granulomas [30]. This evidence concerns the gene SLC44A4 and Granuloma.